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Abstract
Introduction—Identifying pregnant women with hepatitis B virus (HBV) infection for post-
exposure prophylaxis of their infants is critical to preventing mother-to-child transmission of HBV 
infection. HBV infection in infancy results in premature death from chronic liver disease or cancer 
in 25% of affected infants. Universal screening of pregnant women for HBV infection is the 
standard of care, and in many states is supported by laws for screening and reporting these 
infections to public health. No recent assessment of state screening and reporting laws for HBV 
infection has been published.
Methods—In 2014, the authors analyzed laws current through December 31, 2013 from U.S. 
jurisdictions (50 states and the District of Columbia) related to HBV infection and hepatitis B 
surface antigen screening and reporting requirements generally and for pregnant women 
specifically.
Results—All states require reporting of cases of HBV infection. Twenty-six states require 
pregnant women to be screened. Thirty-three states require public health reporting of HBV 
infections in pregnant women, but only 12 states require reporting pregnancy status of women 
with HBV infection.
Conclusions—This assessment revealed significant variability in laws related to screening and 
reporting of HBV infection among pregnant women in the U.S. Implementing comprehensive 
HBV infection screening and reporting laws for pregnant women may facilitate identifying HBV-
infected pregnant women and preventing HBV infection in their infants.
Introduction
Screening pregnant women for hepatitis B virus (HBV) infection is the standard of care in 
the U.S. because mother-to-child transmission (MTCT) of HBV infection is considered 
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preventable.1–4 HBV infection progresses to chronic HBV infection in 90% of infants and 
results in premature death from liver failure or liver cancer in approximately 25%.1,2 When 
post-exposure prophylaxis (PEP) for HBV-exposed infants is initiated within 12 hours of 
birth, it prevents 95% of HBV infections via MTCT.1 Improved identification of pregnant 
women with HBV infection allows public health authorities to assist medical providers 
ensure high rates of PEP administration for these infants. Screening and reporting laws have 
the potential to increase identification of pregnant women with HBV infection, particularly 
through laboratory reporting.5
To prevent MTCT of HBV infection, PEP initiated within 12 hours of birth begins with 
administration of HBV immunoglobulin and the first dose of the HBV vaccination series. 
PEP is considered complete after post-vaccination serologic testing of the infants at age 9–
12 months. The results of testing determine whether the infants have vaccine protection, 
immunity, or chronic HBV infection.2,6
Since 1988, the Advisory Committee on Immunization Practices of the Centers for Disease 
Control and Prevention (CDC) has recommended screening all pregnant women for HBV 
infection at the first prenatal visit of each pregnancy.7 Screening identifies HBV-infected 
pregnant women whose infants are at risk for MTCT of HBV infection; identifying at-risk 
infants prior to their birth and notifying birth hospitals helps ensure that these infants receive 
appropriate PEP at birth.2 Hepatitis B surface antigen (HBsAg) is the serologic marker 
recommended for determining HBV infection in pregnant women (Table 1).2 Additional 
testing is recommended for HBsAg-positive individuals. This testing usually includes 
hepatitis B e antigen (HBeAg), hepatitis B viral load (HBV DNA), and liver enzymes to 
assess liver disease activity and the need for considering antiviral treatment.8–11
In 1990, the Perinatal Hepatitis B Prevention Program (PHBPP) was created within CDC-
funded public health immunization programs to accelerate elimination of MTCT of HBV 
infection.12 CDC is authorized under Section 317 of the Public Health Service Act of 1963 
to award funds for PHBPP activities in 64 immunization programs, including the 50 states 
and the District of Columbia (DC). PHBPP coordinators seek to identify all pregnant women 
with HBV infection in their jurisdiction and to assist pregnant women and their providers 
(both public and private) to ensure optimal PEP for HBV-exposed infants. HBV-infected 
pregnant women are not evenly distributed throughout the U.S. For example, in 2013, five 
states (California, Texas, New Jersey, Florida, and Georgia) identified 3,907 (42%) births to 
HBsAg-positive women identified by PHBPPs in the 50 states and DC (CDC, unpublished 
data, 2014).
Historically, HBV infection has been reportable to state public health departments, including 
PHBPPs throughout the U.S.5 Although public health requirements for reporting specific 
serologic markers of HBV infection vary, results of positive tests for HBsAg are commonly 
required. The federal Clinical Laboratory Improvement Amendment requires that providers 
ordering laboratory tests include information on patient sex and age or birth date, but does 
not require information on pregnancy status.13 The lack of an indicator of pregnancy status 
in HBV case reports is a barrier for PHBPP coordinators attempting to identify HBsAg-
positive pregnant women from among all received reports, increasing the chance that HBV-
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infected pregnant women will be missed. PHBPPs seek notification of possible pregnant 
HBV cases from various sources, including required notifiable disease reporting by 
laboratories, physicians, and hospitals.14 Some states document maternal HBsAg status on 
the birth certificate or document administration of PEP at birth in the state’s immunization 
information system, also known as an immunization registry (N. Fenlon, CDC, personal 
communication, 2016).14,15
This analysis examined state laws to determine whether requirements exist that could help 
public health programs identify HBV-infected pregnant women, and achieve the Health and 
Human Services Viral Hepatitis Action Plan (2014) goal of eliminating perinatal HBV 
transmission.
Methods
This study was based on methods used in a 2006 assessment of state laws pertaining to 
vaccination of healthcare workers and patients.16 For this assessment, researchers again 
evaluated laws of the 50 states and DC, but limited the scope to those pertaining to HBV 
infection. The study was conducted by CDC’s Public Health Law Program. Researchers 
examined the following two questions: Does the jurisdiction require screening of pregnant 
women specifically for HBV infection or HBsAg? Does the jurisdiction require reporting of 
HBV infection or HBsAg in pregnant women?
The current assessment also examined two additional questions to give a more complete 
picture of how HBV infection in pregnant women is reported: Does the jurisdiction require 
general reporting of HBV infection? Does the jurisdiction require reporting the pregnancy 
status of women who have HBV infection or who test positive for HBsAg?
Researchers used WestlawNext, a subscription-only, online legal research service 
(www.westlaw.com), to systematically identify all statutes and regulations pertaining to 
screening and reporting of HBV infection and HBsAg of the population generally, and of 
pregnant women specifically. Researchers first searched the statutory code and 
administrative regulations of each state, as well as municipal regulations from DC, using the 
search term hepatitis B (n=51 jurisdictions). Laws pertaining to reporting HBV or HBsAg-
positive infections and to screening pregnant women were reviewed. Specific characteristics 
were analyzed and coded and then entered into a database. Analysis was performed on laws 
through December 31, 2013. Researchers analyzed statutes and regulations by jurisdiction 
and determined screening and reporting requirements using generally accepted rules and 
conventions of statutory interpretation.17
Screening laws were analyzed for the timing of the screening, the parties responsible for 
screening, and requirements for screening high-risk pregnant women.2 Reporting laws were 
analyzed to determine what types of HBV laboratory markers must be reported, parties 
responsible for reporting, and when cases of HBV infection must be reported to public 
health authorities. Using t-tests, researchers looked for an effect of state screening and 
reporting laws on the mean proportion of infants born to HBsAg-positive women in 2013. 
The identified number of infants was taken from PHBPP program data, and the expected 
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number of infants was based on CDC models.12 Because this study did not involve human 
subjects, no human subjects review was conducted.
Results
Twenty-six states require pregnant women to be screened for HBV infection or HBsAg 
(Table 2). Nineteen states require pregnant women to be screened at the initial prenatal visit 
or shortly thereafter. For example, Kansas law states that women must be screened “within 
14 days after diagnosis of pregnancy”18; Pennsylvania provides that screening must occur 
“at the time of the first examination (including the initial visit when a pregnancy test is 
positive) or within 15 days thereafter”19; and Washington requires screening “during the first 
trimester of pregnancy.”20 Two of these states, Arkansas and Florida, require all pregnant 
women to be screened during the third trimester, in addition to the initial screening.
Ten states require pregnant women to be screened at admission for delivery if there is no 
record of HBV test results during the pregnancy. Arkansas, for example, requires screening 
pregnant women “if not attended prenatally, at the time of delivery.”21 New Jersey law 
highlights the availability of the test results, requiring “[a] ll pregnant women admitted to the 
hospital with unknown or undocumented hepatitis B surface antigen (HBsAg) assay results 
shall be immediately screened for the hepatitis B virus using the HBsAg test or other 
standardized hepatitis B tests.”22 Alaska’s provision applies only to birth centers and 
requires that “[i]f a client requests the services of the birth center late in pregnancy and has 
no evidence of ongoing prenatal care, the birth center shall ensure that (1) the risk 
assessment … includes necessary laboratory testing,” including screening for hepatitis.23 
Texas requires pregnant women to be screened at admission for delivery in addition to the 
initial screening, regardless of known or suspected risk factors.24 In addition to requiring 
screening at admission for delivery if there is no record of test results, New York has a 
second screening law (with an indeterminate timing requirement), namely, when the 
“healthcare provider attending a pregnant woman takes a blood sample to be tested for 
syphilis or at another time when blood is drawn during prenatal care.”25
Nineteen of the jurisdictions requiring prenatal screening assign the prenatal care 
practitioner the responsibility for ensuring pregnant women are screened. Some states’ laws 
enumerate the medical professionals who are required to screen for HBV infection. For 
example, Missouri requires, “[e]very licensed physician, midwife, registered nurse, and all 
persons who may undertake, in a professional way, the obstetrical and gynecological care of 
a pregnant woman” to screen for HBV.26 Other states designate the party responsible for 
screening using a more general term that may or may not be defined elsewhere in statute. 
For example, Hawaii law simply states that “[t]he attending practitioner” must conduct the 
screening.27 Four states (Alaska, Colorado, Minnesota, New Hampshire) require midwives 
to screen for HBV infection during pregnancy but do not indicate a requirement for other 
obstetric providers.
Six states require additional testing during the third trimester or upon admission for delivery 
for women considered at high risk for acquiring HBV infection during pregnancy. States 
differ as to how they define women at high risk for HBV. For example, Florida defines high-
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risk women as those who appear at delivery or within 30 days postpartum with no record of 
prenatal care, no record of testing, or no record of testing after 27 weeks gestation.28 Illinois 
defines high-risk women as those with a recent history of a sexually transmitted disease, 
injection drug use, or other possible risk factors for HBV infection.29
All jurisdictions examined require reporting of cases of HBV infection (Table 3). Thirty-two 
states and DC require reporting HBV infections and HBsAg in pregnant women. Twelve 
states require reporting the pregnancy status of women with HBV infection or who test 
positive for HBsAg; no state laws explicitly prohibit the capture or recording of pregnancy 
status of women who are screened. Seven states require reporting positive HBeAg or HBV 
DNA test results in pregnant women.
Healthcare providers are named the responsible party for reporting HBV infection cases in 
49 jurisdictions (all except North Carolina and DC). Laboratories are required to report HBV 
infection cases in 49 jurisdictions (all except Missouri and DC). Hospitals or other 
healthcare facilities are required to report HBV infection cases in 33 states. DC’s municipal 
regulation states that HBV infection, “shall be reported in writing within forty-eight (48) 
hours of diagnosis or the appearance of suspicious symptoms,” but does not specify which 
parties must report cases of HBV infection.30
Twenty-seven states require reporting within 1 day of diagnosis or positive laboratory test 
result. Twenty-nine states require reporting within 2–7 days of diagnosis, and two states 
(Arizona and Washington) require reporting within 30 days of diagnosis. These categories of 
timing requirements for reporting are not mutually exclusive; some states have different time 
interval reporting requirements for different reporting entities or different methods of 
diagnosis (e.g., laboratory test versus clinical diagnosis). Nine states have different time 
interval requirements for different diagnoses: for example, Indiana requires HBV infection 
cases to be reported within 72 hours, but HBV infection in pregnant women or in perinatally 
exposed infants must be reported immediately.31 By contrast, Maine mandates that acute 
cases of HBV be reported immediately, whereas all other cases must be reported within 48 
hours of diagnosis.32 Five states do not have specific timing requirements for reporting of 
HBV infection (Table 3).
In an analysis of 2013 data for infants born to HBsAg-positive women, there was no 
statistically significant difference in the mean proportion of identified-to-expected number of 
infants in states with or without screening laws. Similarly, there was no statistically 
significant difference in the mean proportion of identified-to-expected number of infants in 
states with or without reporting laws.
Discussion
Because PEP is an effective means to prevent MTCT of HBV infection and significantly 
decrease long-term morbidity and mortality resulting from chronic HBV infection, it is 
important that every pregnant woman with HBV infection be identified so her infant can 
receive PEP. For this reason, states have developed explicit requirements for screening and 
reporting rather than simply relying on adherence to standard of care. Although it is 
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unknown what proportion of reporting is attributable to the presence of a law versus a 
provider’s desire to benefit public health, laws likely have an effect. An evaluation of the 
New York State PHBPP cited state laws requiring universal testing and reporting of pregnant 
women with HBV infection as the primary factor leading to a 96% case ascertainment rate 
and 92% of infants born to reported mothers receiving PEP within 48 hours of birth.15
This assessment revealed significant variability in laws related to screening and reporting of 
HBV infection among pregnant women in U.S. public health jurisdictions. Only 26 of 51 
jurisdictions require that providers screen for HBV infection among pregnant women, 
despite the significant health risks to infants born to infected mothers. Because of the 
important individual and public health consequences of HBV infection, all jurisdictions 
require reporting of HBV infection (including HBsAg-positive pregnant women). However, 
researchers found that only 12 of 51 jurisdictions require reporting of pregnancy status for 
HBV-infected women.
Failing to identify HBsAg-positive pregnant women increases the risk that the brief 
“window” of opportunity to initiate prevention of MTCT of HBV infection will be missed. 
Identification of HBV-infected pregnant women among all reported HBV-infected women is 
labor intensive for PHBPPs, and may require review and follow-up of thousands of reports 
of positive HBV test results. When identified and case managed by PHBPPs, the rates of 
chronic HBV infection among exposed infants who received post-vaccination testing was as 
low as 0.5% (CDC, unpublished data, 2014). Rates of MTCT can be as high as 90% among 
infants who miss timely PEP.2 In contrast with previous studies, this analysis did not 
demonstrate an effect of state screening or reporting laws on identification of infants born to 
HBV-infected women.15 This may be due to differential compliance with existing laws or 
uncertainties in the data used to calculate the expected number of infants born to infected 
women.12
National advisory committees recommend that people with chronic HBV infection, 
including pregnant women, receive counseling and medical evaluation for care and 
treatment.2,10 Evaluation generally includes HBV-specific tests, such as the presence of 
HBeAg or the HBV DNA level.10 In this review, 33 states require reporting of positive 
markers for HBV, but only seven states have statutes specifically requiring reporting of 
positive HBeAg or HBV DNA results. Only one of these states (Arizona) requires both 
reporting of pregnancy status and HBeAg or HBV DNA. Laws that require reporting of 
HBeAg positivity or DNA results in addition to pregnancy status may assist city and state 
PHBPPs to educate providers on options for achieving successful prevention of MTCT of 
HBV infection.33–36 CDC and the American College of Obstetricians and Gynecologists 
offer an algorithm indicating prenatal HBeAg or HBV DNA testing should be included in 
the initial evaluation of HBsAg-positive women.10 If these tests meet certain criteria defined 
by the algorithm, the women should have a prenatal consultation with a provider skilled in 
the management of chronic HBV.
Limitations
First, this assessment was restricted to statutes and regulations in U.S. state jurisdictions and 
DC; relevant laws may also exist in counties or municipalities. Second, researchers did not 
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comprehensively review case law, professional licensing board opinions or rules, and other 
enforcement guidance, such as opinions from attorneys general, that could affect HBV 
screening and reporting. Therefore, the analysis might not fully reflect reporting or 
screening requirements in a jurisdiction. Third, the analysis did not examine how the law 
was applied in practice. Compliance might vary from jurisdiction to jurisdiction—or even 
within a jurisdiction—depending on whether public health authorities have sufficient 
resources to educate and enforce screening and reporting laws. It might vary with 
practitioners’ awareness and understanding of a law, whether they perceive it is enforced, 
and whether they believe the benefits of noncompliance outweigh any penalties. Finally, the 
results of this analysis provide a snapshot at the end of 2013, and some laws might have 
changed since then.
Conclusions
Screening and reporting requirements are an important tool for early identification of HBV 
infection in pregnant women and, consequently, an important tool in the prevention and 
identification of HBV infection in their infants. As new laws are considered to reduce 
MTCT of HBV infection, several provisions to increase the effectiveness of screening and 
reporting could be considered. Requiring all pregnant women to be screened for HBsAg at 
either the initial prenatal visit or at admission for delivery if there is no record of test results, 
and reporting pregnancy status in HBsAg-positive women, could increase the number of 
women identified for prenatal intervention. Requiring reporting of positive test results within 
1 day could increase the number of women identified in time for intervention. Finally, 
screening laws that are inclusive of all types of obstetric care providers (e.g., including 
unlicensed midwives) can help to ensure universal screening for HBV infection among 
pregnant women. Ultimately, implementation of comprehensive HBV infection screening 
and reporting laws for pregnant women could accelerate efforts by public health and medical 
professionals to reduce chronic HBV infection and fatal liver disease in the U.S.
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Table 1
Laboratory Markers of HBV Infection
Marker name Abbreviation Description
Hepatitis B virus HBV Virus causing hepatitis B infection
Hepatitis B surface antigen HBsAg Protein present on the surface of hepatitis B virus; the principal marker of 
acute and chronic HBV infection
Hepatitis B e antigen HBeAg Protein present during active replication of hepatitis B virus; indicates an 
increased risk of transmitting HBV
Hepatitis B viral DNA HBV DNA Indicates active HBV infection
Antibody to hepatitis B core antigen (IgG 
and IgM)
Anti-HBc, total Indicates acute, chronic, or resolved HBV infection; often persists for life
IgG, immunoglobulin G; IgM, immunoglobulin M.
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Table 2
Legal Provisions for HBV Infection Screening for Pregnant Women
Legal provision Jurisdictions, n Jurisdictions
Screening
 Require pregnant women be screened for HBV infection or HBsAg 26 AK, AR, CA, CO, DC, FL, HI, IL, KS, KY, 
MI, MN, MO, MT, NV, NH, NJ, NY, NC, OR, 
PA, TN, TX, UT, VA, WA
Screening: timing
 Require screening at the initial prenatal visit or shortly thereafter 19 AK, AR, CA, CO, DC, FL, IL, KS, MI, MO, 
MT, NH, OR, PA, TN, TX, UT, VA, WA
 Require screening at admission for delivery if there is no record of test 
results
10 AK, AR, CA, DC, MI, MO, NJ, NY, TN, UT
 Require screening during the third trimester in addition to the initial 
screening for all women
  2 AR, FL
 Require screening at admission to delivery in addition to the initial 
screening for all women
  1 TX
Screening: responsible party
 Require the attending practitioner to ensure the woman is screened 19 AR, CA, DC, FL, HI, KS, KY, MI, MO, MT, 
NV, NJ, NY, OR, PA, TN, TX, UT, VA
 Only require midwives to ensure the woman is screened   4 AK, CO, MN, NH
 Party responsible for screening not specified   3 IL, NC,WA
Screening: high-risk women
 Require additional testing during the third trimester or upon admission 
for delivery for women who are considered high risk
  6 FL, IL, TN, UT, VA, WA
HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus.
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Table 3
Legal Provisions for HBV Infection Reporting
Characteristics Legal provision Jurisdictions, n Jurisdictions
Reporting Require general reporting of hepatitis 
B
51 All (50 states + DC)
Require reporting of HBV infection or 
HBsAg in pregnant women
33 AZ, AR, CA, CT, DC, FL, GA, HI, IL, IN, KS, 
KY, LA, ME, MI, MN, MS, MO, MT, NV, NH, 
NJ, NY, NC, OH, OK, RI, TN, TX, UT, VT, 
WA, WV
Require reporting of pregnancy status 
in women who have HBV infection or 
who test positive for HBsA
12 AK, AZ, FL, IA, KS, MD, MN, NE, TX, UT, 
VA, WY
Reporting: what must be 
reported
Case or suspected case of HBV 
infection
51 All (50 states + DC)
Positive laboratory markers for 
hepatitis B
33 AK, AZ, AR, CA, CO, CT, DC, FL, HI, ID, IL, 
KY, LA, MI, MN, MS, MO, NE, NH, NJ, NY, 
NC, OK, OR, PA, RI, SC, TN, UT, VT, VA, 
WA, WV
HBeAg or HBV DNA results   7 AL, AZ, CO, IN, OK, VT, WA
Reporting: responsible party Providers (all types) 49 All except D.C. and NCa
Laboratories 49 All except D.C. and MO
Other—hospital and healthcare facility 
administrators
33 AL, CA, CO, CT, DE, FL, GA, ID, IN, KS, KY, 
ME, MD, MN, MO, MT, NE, NV, NJ, NY, ND, 
OK, OR, PA, RI, SC, SD, TX, UT, VA, WA, 
WI, WY
No responsible party specified   1 DC
Reporting: timing ≤1 day (includes immediate, ≤24 
hours, or next business day)
27 AR, CA, CT, FL, ID, IN, KY, LA, ME, MD, 
MA, MI, MN, NJ, NM, NY, NC, ND, OH, OK, 
OR, PA, TX, VT, WA, WV, WY
2–7 days (includes 48 hours, 72 hours, 
within 3 days, within 5 days, or within 
7 days)
29 AL, AK, CO, CT, DE, DC, ID, IL, IN, IA, KS, 
LA, ME, MS, MO, MT, NE, NH, NJ, NC, OH, 
PA, SD, TN, TX, UT, VA, WA, WI
>7 days (includes within 30 calendar 
days)
  2 AZ, WA
Different time intervals for different 
hepatitis B diagnoses (e.g., perinatal, 
pregnancy, acute, or chronic)
  9 IL, IN, LA, ME, NC, OH, OK, TX, WA
Not specified   5 GA, HI, NV, RI, SC
aNorth Carolina requires only laboratories to report cases of hepatitis B, not providers.
HBeAg, bepatitis B e antigen; HBsAg, bepatitis B surface antigen; HBV, hepatitis B virus.
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